T cells were no longer able to exert their cytotoxic activity, because of either a lack of tumor antigen recognition and activation or a loss of sensitivity to their effector molecules by the cancer cells. The general possibilities are loss of mutational or shared tumor antigens that are recognized by T cells, loss of antigen-presenting machinery components (e.g., beta-2-microglobulin and HLA),12-14 tumor-cell–induced or myeloid-cell–induced inactivation of T-cell signaling,32,33 or insensitivity to the proapoptotic effects of toxic granules (e.g., perforin and granzymes), death receptors (e.g., Fas and tumor necrosis factor–related apoptosis-inducing ligand [TRAIL]), or interferons.
http://www.nejm.org/doi/full/10.1056/NEJMoa1604958#t=articleDiscussion
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM